Percutaneous microwave ablation and transcatheter arterial chemoembolization for serum tumor markers and prognostics of middle-late primary hepatic carcinoma

Table 5 Univariate analysis affecting the prognosis of patients with mid-late PHC

Item	Death group (n = 46)	Survival group (n = 104)	χ2	P value
Gender (male/female)	21/25	63/41	2.883	0.090
Age (yr)			0.403	0.836
≥ 60	16 (34.78)	38 (36.54)
< 60	30 (65.22)	66 (63.46)
Tumor diameter (cm)			17.559	< 0.0012
≥ 6	31 (67.39)	32 (30.77)
< 6	15 (32.61)	72 (69.23)
Tumor number (cases)			23.588	< 0.0012
Single	17 (36.96)	81 (77.88)
Multiple	29 (63.04)	23 (22.12)
Treatment method (cases)			6.145	0.0131
Single TACE	30 (65.22)	45 (43.27)
TACE + PMCT	16 (34.78)	59 (56.73)

¹P < 0.05.

²P < 0.0001.

TACE: Transcatheter arterial chemoembolization; PMCT: Percutaneous microwave coagulation therapy.